21577-80-0Relevant academic research and scientific papers
A surfactant
-
Paragraph 0056; 0057; 0058; 0059, (2017/08/25)
The invention discloses a surfactant for driving oil. The surfactant is prepared through the following method. The method comprises steps: first, an intermediate myristyl allyl dibromo tetramethyl ethylenediamine is synthesized; second, myristyl allyl dibromo tetramethyl ethylenediamine is synthesized. The intermediate is dissolved completely in ethyl acetate, the constant temperature of 50-60 DEG C is achieved, 3-bromopropylene is added in the reaction system, after the reaction is carried out at a constant temperature with stirring for 4h, pressure reduction pumping filtration is carried out, and white solid is obtained. The white solid is subjected to recrystallization for two times by utilization of ether, drying is carried out until a constant weight is achieved, and the surfactant for driving oil is prepared. Myristyl allyl dibromo tetramethyl ethylenediamine also can be compounded with sodium phthalate of mono lauryl alcohol according to a weight ratio of 1:0.2-1, and a compound surfactant for driving oil is obtained. The synthesis technology conditions are simple, products are easy to separate, the yield is high, and industrialization is easy. Performances of the product such as salt resistance, temperature resistance, foaming property and foam stability, oil water interface tension force and the like are better than that of a traditional surfactant for driving oil.
PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF
-
Page/Page column 8, (2012/03/26)
Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.
Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof
-
Page/Page column 5, (2012/04/18)
Prodrugs based on gemcitabine structure shown in formula (I) as well as their synthetic method and application are disclosed in the present invention, wherein the definitions for the groups of a, b, c, d, E, Z and V are described in the specification. By modifying the N4 group, the solubility, the bioavailability and the organ specificity of the prodrugs are improved. Therefore, the fast metabolism problem is overcome for the produced prodrugs compounds. Intestinal toxicity induced by gemcitabine is decreased. Thereby, the prodrugs can be delivered by oral administration in clinics and further improve their anti-tumor, anti-cancer, anti-infection and diffusion preventing capability, and can also specifically act on liver or colon. The synthetic method is simple and adapted to industrial production.
Synthesis and Biological Evaluation of Oral Prodrugs Based on the Structure of Gemcitabine
Zhao, Cuirong,Xue, Xiaoxia,Li, Gang,Sun, Cuicui,Sun, Changjun,Qu, Xianjun,Li, Wenbao
experimental part, p. 479 - 488 (2012/10/07)
A series of oral prodrugs based on the structure of gemcitabine (2′,2′-difluorodeoxycytidine) were synthesised by introducing an amide group at the N4-position of the cytidine ring. A total of 16 compounds were obtained, and their chemical and biological characteristics were evaluated. The half-maximal inhibitory concentrations (IC50s) for most of these compounds were higher than that of gemcitabine in vitro. Compounds 5d and 5m, the representative compounds, were examined in terms of their physiological stabilities and pharmacokinetics. Compound 5d showed good stability in PBS and simulated intestinal fluid, and an analysis of its pharmacokinetics in mice suggested that the introduction of an amide group to gemcitabine could greatly improve its bioavailability. Further evaluation of compound 5din vivo showed that this compound possesses higher activity than gemcitabine against the growth of HepG2 human hepatocellular carcinoma cells and HCT-116 colon adenocarcinoma cells with less toxicity to animals. These results suggest that compound 5d could be further developed as a potential oral anticancer agent for clinical applications in which gemcitabine is currently used. A series of oral prodrugs based on the structure of gemcitabine were synthesized. Physiological and metabolic stabilities, pharmacokinetics and antitumor activities were evaluated for representative compounds.
NOUVEAUX DECONTAMINANTS. ACTION DES PERACIDES A GROUPE ESTER SUR QUELQUES TOXIQUES INSECTICIDES OU DE GUERRE
Lion, C.,Hedayatullah, M.,Bauer, P.,Boukou-Poba, J. P.,Charvy, C.,et al.
, p. 555 - 560 (2007/10/02)
A new peroxyacid-ester series has been obtained and used in the destruction of toxic agents.These structures oROCOC6H4CO3H and ROCO(CH2)nCO3H are more stable than the unsubstituted compounds.The reaction with paraoxon (O,O-diethyl O-paranitrophenylphosphate) and HD (2,2'-dichlorodiethylsulfide) goes to completion in a very short time.The influence of the R group and the length of the chain (n=2......12) has been studied.The addition of some long chain tetraalkyl-ammonium salts enhances the rate of the reaction by micellar catalysis.
